Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | TP53 | P04637 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.87 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.86 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059060 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL70748 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL13567361 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL1060273 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrahexylammonium SCHEMBL2521928 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL332137 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL1065743 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL4059099 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL1009645 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL4685770 | 1.00 | SLC22A1 (0.93) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0736130-B1 | A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES | SHELL INT RESEARCH (NL) | 1998-07-15 | — | — | EP | claimed |
| US-5648575-A | Method for inhibiting the plugging of conduits by gas hydrates | SHELL OIL COMPANY (US) | 1997-07-15 | — | — | US | claimed |
| EP-0736130-A1 | A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1996-10-09 | — | — | EP | claimed |
| US-5460728-A | Using quaternary ammonium compound as inhibitor of hydrate formation | SHELL OIL COMPANY (US) | 1995-10-24 | — | — | US | claimed |
| WO-1995017579-A1 | A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1995-06-29 | — | — | WO | claimed |
| US-20250312360-A1 | MITOCHONDRIAL ANTIOXIDANT TREATMENT FOR CASK-LINKED NEURODEVELOPMENTAL DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250312730-A1 | ACIDIC GAS ABSORBENTS COMPRISING IONIC LIQUIDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2025-10-09 | — | — | US | disclosed |
| US-20250122323-A1 | ONIUM SALT, BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANTE COMPOSITION INCLUDING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, AND CURED PRODUCT AND MANUFACTURING METHOD THEREFOR | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2025-04-17 | — | — | US | disclosed |
| EP-4514528-A1 | ACIDIC GAS ABSORBENTS COMPRISING IONIC LIQUIDS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2025-03-05 | — | — | EP | disclosed |
| CN-117813334-A | Onium salt, blocking agent dissociation catalyst for blocking isocyanate, blocked isocyanate composition containing blocking agent dissociation catalyst, thermosetting resin composition, cured product, and method for producing same | 广荣化学株式会社 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023220365-A1 | MITOCHONDRIAL ANTIOXIDANT TREATMENT FOR CASK-LINKED NEURODEVELOPMENTAL DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023205851-A1 | ACIDIC GAS ABSORBENTS COMPRISING IONIC LIQUIDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | WO | disclosed |
| WO-2002066785-A1 | COMPOSITION AND METHOD FOR INHIBITION OF FORMATION OF GAS HYDRATES | BAKER HUGHES INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020038063-A1 | Composition and method for inhibition of formation of gas hydrates | BAKER HUGHES INCORPORATED | 2002-03-28 | — | — | US | disclosed |
| US-6080858-A | Process for reacting fluorine-substituted heterocycles with amines in the presence of phase transfer catalysts | DYSTAR TEXTILFARBEN GMBH & CO. DEUTSCHLAND KG (DE) | 2000-06-27 | — | — | US | disclosed |
| EP-0736130-B1 | A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES | SHELL INT RESEARCH (NL) | 1998-07-15 | — | — | EP | disclosed |
| US-5739400-A | Preparation of O-(2-hydroxyalkyl)oximes | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-14 | — | — | US | disclosed |
| EP-0736130-A1 | A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1996-10-09 | — | — | EP | disclosed |
| US-5460728-A | Using quaternary ammonium compound as inhibitor of hydrate formation | SHELL OIL COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995017579-A1 | A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038063-A1 | Composition and method for inhibition of formation of gas hydrates | HDHD5, SHH, NOTUM | SLC22A1 2116/4885ALDH1A1 4272/4885TP53 2953/4885 |
| US-20250122323-A1 | ONIUM SALT, BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANTE COMPOSITION INCLUDING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, AND CURED PRODUCT AND MANUFACTURING METHOD THEREFOR | KDM2B, O60361, IDH3B | SLC22A1 4626/4885ALDH1A1 1023/4885TP53 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.